Novel RXFP3 negative allosteric modulator RLX-33 reduces alcohol self-administration in rats.

ABSTRACT: There is much interest in identifying novel pharmacotherapeutic targets that improve clinical outcomes for the treatment of alcohol use disorder (AUD). One promising target for therapeutic intervention is the relaxin family peptide 3 (RXFP3) receptor, a cognate receptor for neuropeptide relaxin-3, which has previously been implicated in regulating alcohol drinking behavior. Recently, we developed the first small-molecule RXFP3-selective negative allosteric modulator (NAM) RLX-33. Therefore, the goal of the present work was to characterize the impact of this novel NAM on affective-related behaviors and alcohol self-administration in rats. First, the effects of RLX-33 were tested on alcohol and sucrose self-administration in Wistar and alcohol-preferring P rats to determine the dose-response

SUBMITTER: Van Voorhies KJ 

PROVIDER: S-EPMC10592109 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature